Leo CEO Bourdon Plots Return To Profit This Year
As Early-Stage R&D Is Axed
The Danish group has cut 300 jobs to shift to an external innovation sourcing model that will make Leo more competitive in the dermatology space and help it break even this year, CEO Christophe Bourdon tells Scrip.
